Dry Eye

In addition to these tips on preventing digital eye strain, it is important to implement other eye-healthy habits.

The authors conducted a prospective non-interventional study in which a self-questionnaire was used to evaluate the ocular symptoms and medical background of patients with KC and OSD who engage in chronic eye rubbing.

An important take-away was the total and central corneal staining score improving after only 2 weeks of treatment.

Recommending a nighttime eye mask and ear plugs may protect the ocular surface.

Dirty equipment and sterilization issues are among the many violations found by the FDA.

Nasal spray may fill the gaps left by artificial tears.

Women are at higher risk of eye disease than men.

A look back on what happened in optometry during the week ofMarch 27-March 31.

Investigators reported that moderate to severe Meibomian gland dysfunction (MGD) was treated successfully with a 3-week course of weekly oral azithromycin that was equivalent to a 6-week course of oral doxycyclin.

A look back on what happened in optometry during the week of March 20-March 24.

The second pivotal phase 3 data on NOV03 (perfluorohexyloctane) show that NOV30 consistently met primary endpoints for signs and symptoms of dry eye disease associated with Meibomian gland dysfunction.

Catch up on what to expect from Lumenis.

How one OD incorporated full-service dry eye treatment.

The ones you should seek out—and avoid.

BRIM Biotechnology’s BRM421 is a first-in-class regenerative peptide and could relieve signs and symptoms of dry eye disease in as little as 2 weeks.

The FDA issued an update to the warning issued early in February and recommended that Global Pharma recall Delsam Pharma’s Artificial Eye Ointment, and the firm agreed to initiate a recall.

A wave of infections across 11 states have been linked to artificial tear use, leading to permanent vision loss, hospitalization, and one death.

A look back on what's happened in optometry during the week of Jan. 14-Jan. 19.

Staying up-to-date on all things ocular is imperative in ocular surface disease.

Novel drops for a variety of indications are under investigation.

A look back on what's happened in optometry during the week of Jan. 7-Jan. 12, 2023.

Patient quality of life has been shown to be severely impaired by the associated ocular surface symptoms, so treatment aims for symptomatic relief and prevention of further damage to the ocular surface.

A look back on what's happened in optometry during the week of Jan. 1-Jan. 5, 2023.

Diagnosing and treating dry eye and meibomian gland dysfunction can be the foundation for practice growth—and patient satisfaction.

Marc R. Bloomenstein, OD, FAAO, gives an overview of the SAHARA study.